Nipent Related Clinical Trials
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant [Recruiting]
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies [Recruiting]
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies [Recruiting]
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma [Recruiting]
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Recruiting]
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies [Completed]
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. [Recruiting]
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia [Recruiting]
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia [Recruiting]
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan [Active, not recruiting]
Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease [Recruiting]
Dose-Finding Study Using Pentostatin for Injection in the Treatment of Steroid-Refractory aGvHD [Terminated]
Phase II Trial of Pentostatin and Targeted Busulfan [Recruiting]
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma [Recruiting]
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Recruiting]
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation [Recruiting]
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia [Recruiting]
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT [Active, not recruiting]
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children [Recruiting]
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia [Recruiting]
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Recruiting]
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer [Recruiting]
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant [Recruiting]
Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia [Active, not recruiting]
Alemtuzumab and Pentostatin In T-Cell Neoplasms [Recruiting]
Pentostatin, Alemtuzumab, and a Donor Stem Cell Transplant in Treating Patients With High-Risk Cancer [Recruiting]
Pentostatin and Rituximab With or Without Cyclophosphamide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia [Active, not recruiting]
Etanercept, Mycophenolate Mofetil, Denileukin Diftitox, or Pentostatin Combined With Prednisone or Methylprednisolone in Treating Patients With Acute Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant [Recruiting]
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease [Active, not recruiting]
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Recruiting]
Combination of Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin With Steroids [Active, not recruiting]
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer [Recruiting]
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease [Suspended]
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia [Active, not recruiting]
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-Cell Cancers [Active, not recruiting]
Pentostatin and Cyclophosphamide Followed By Donor Stem Cell Transplant and Donor Lymphocyte Infusions in Patients With Metastatic Kidney Cancer [Recruiting]
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Completed]
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer [Recruiting]
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer [Completed]
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab [Recruiting]
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma [Active, not recruiting]
GVH 0313: Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation [Recruiting]
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients [Active, not recruiting]
Reduced-Intensity Regimen Before Allogeneic Bone Marrow Transplantation in Treating Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma [Active, not recruiting]
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes [Recruiting]
Treatment for Acute Graft-Versus-Host Disease [Recruiting]
Natural Killer Cells and Bortezomib to Treat Cancer [Recruiting]
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies [Recruiting]
A Phase II Study of Umbilical Cord Blood Transplantation [Recruiting]
|
